{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:38:40Z","timestamp":1787063920172,"version":"build-2736575974"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>In this issue of Blood Cancer Discovery, Kamiya and colleagues identify aberrant RNA splicing as a targetable vulnerability in multiple myeloma. Using the RBM39 degrader indisulam, they show that therapeutic modulation of RNA splicing factors is a potential treatment strategy for patients with therapy-resistant multiple myeloma.<\/jats:p>\n                  <jats:p>See related article by Kamiya et al., p. 602<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-25-0308","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:32Z","timestamp":1760104232000},"page":"535-537","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RNA Splicing as a Therapeutic Vulnerability in Therapy-Refractory Multiple Myeloma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7809-5888","authenticated-orcid":false,"given":"Maxim I.","family":"Maron","sequence":"first","affiliation":[{"name":"Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-6171","authenticated-orcid":false,"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025110303134716600_bib1","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.molcel.2024.07.019","article-title":"Molecular impact of mutations in RNA splicing factors in cancer","volume":"84","author":"Zhang","year":"2024","journal-title":"Mol Cell"},{"key":"2025110303134716600_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/2643-3230.BCD-24-0340","article-title":"Identification of a CD138-negative therapy-resistant subpopulation in multiple myeloma with vulnerability to splicing factor inhibition","volume":"6","author":"Kamiya","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2025110303134716600_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025110303134716600_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41408-022-00759-6","article-title":"In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors","volume":"12","author":"Aktas Samur","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025110303134716600_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-022-02124-7","article-title":"Dysregulation of alternative splicing contributes to multiple myeloma pathogenesis","volume":"128","author":"Song","year":"2023","journal-title":"Br J Cancer"},{"key":"2025110303134716600_bib6","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1002\/ctm2.684","article-title":"Splicing factor arginine\/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Med"},{"key":"2025110303134716600_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2025110303134716600_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"2025110303134716600_bib9","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"key":"2025110303134716600_bib10","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.cell.2025.03.047","article-title":"Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias","volume":"188","author":"Kim","year":"2025","journal-title":"Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0308\/3659195\/bcd-25-0308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/535\/3663371\/bcd-25-0308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/535\/3663371\/bcd-25-0308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:13:52Z","timestamp":1762157632000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/535\/766813\/RNA-Splicing-as-a-Therapeutic-Vulnerability-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0308","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}